Search results for "PROGRESSION"

showing 10 items of 1251 documents

American Association Of Clinical Endocrinologists, American College Of Endocrinology, And Androgen Excess And Pcos Society Disease State Clinical Rev…

2015

Polycystic Ovary Syndrome (PCOS) is recognized as the most common endocrine disorder of reproductive-aged women around the world. This document, produced by the collaboration of the American Association of Clinical Endocrinologists (AACE) and the Androgen Excess and PCOS Society (AES) aims to highlight the most important clinical issues confronting physicians and their patients with PCOS. It is a summary of current best practices in 2015. PCOS has been defined using various criteria, including menstrual irregularity, hyperandrogenism, and polycystic ovary morphology (PCOM). General agreement exists among specialty society guidelines that the diagnosis of PCOS must be based on the presence o…

medicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismType 2 diabetesAndrogen ExcessSeverity of Illness IndexLipoprotein particleFlutamideAnovulationImpaired glucose tolerancechemistry.chemical_compoundEndocrinologyInsulin resistancePregnancyInternal medicinemedicineHumansLife StylehirsutismMetabolic Syndromebusiness.industryHyperandrogenismnutritional and metabolic diseasesGeneral Medicinemedicine.diseasePolycystic ovaryPolycystic ovarian diseaseGestational diabetesEndocrinologyDiabetes Mellitus Type 2chemistryDisease ProgressionSpironolactoneFemaleInsulin ResistanceMetabolic syndromeHyperandrogenismbusinessInfertility FemaleAlgorithmsPolycystic Ovary SyndromeEndocrine Practice
researchProduct

Langzeitverlauf und angiographische Befunde bei serpiginöser Choroiditis

2006

Background: Long-term follow-up and angiographic findings of serpiginous choroiditis, a chronic disease with recurrences of unknown origin, are reported. Patients and Methods: A retrospective analysis of the data of 4 patients with serpiginous choroidopathy, who were treated in the eye clinic of Mainz in the past 10-18 years was made. Progression of disease was documented by photography, as well as fluorescein and indocyanine green angiography. Patients with acute lesions were treated with steroids per os for some weeks. Results: All 8 eyes developed 2 - 7 recurrences with progression of the chorioretinal scars. In cases of macular involvement the functional results were worse. No choroidal…

medicine.medical_specialtymedicine.diagnostic_testSerpiginous choroiditisbusiness.industryIndocyanine green angiographyFluorescein angiographymedicine.diseaseeye diseasesOphthalmologychemistry.chemical_compoundChronic diseasechemistryOphthalmologyRetrospective analysisMedicinesense organsFluoresceinbusinessMacular involvementClinical progressionKlinische Monatsblätter für Augenheilkunde
researchProduct

Transdermal estrogens do not appear to modify the extent of lesional areas of aortic atherosclerosis in oophorectomized rabbits on a cholesterol-rich…

2000

Cardiovascular disease (CVD) is the leading cause of death in older women in industrialised countries. It has been suggested that it is the cessation of estrogen production by the ovaries that puts postmenopausal women at increased risk of CVD. Estrogen therapy has demonstrated a protective effect against CVD and several reports suggest that diverse mechanisms may be involved. Oral estrogen appears to be associated with a better lipid profile than the use of transdermal estrogens; however, it is assumed that estrogens, oral and non-oral, have direct actions on the blood vessels that may exert an important role in cardiovascular disease prevention. To investigate the effect of transdermal es…

medicine.medical_specialtymedicine.drug_classArteriosclerosisOvariectomyAortic DiseasesPlaceboAdministration CutaneousCholesterol Dietarychemistry.chemical_compoundTransdermal estrogenInternal medicinemedicineAnimalsTreatment FailureTransdermalmedicine.diagnostic_testEstradiolVascular diseaseCholesterolbusiness.industrymedicine.diseaseEndocrinologychemistryEstrogenDisease ProgressionFemaleTroloxRabbitsCardiology and Cardiovascular MedicineLipid profilebusinessAtherosclerosis
researchProduct

Recent clinical evidence on metronomic dosing in controlled clinical trials: a systematic literature review.

2020

Introduction: Metronomic dosing is used to give continuous chemotherapy at low doses. The low doses have minimal side effects and may enable cancer treatment to be remodeled toward the management o...

medicine.medical_specialtymedicine.medical_treatmentAntineoplastic Agents030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineClinical Trials Phase II as TopicNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingDosingIntensive care medicineRandomized Controlled Trials as TopicChemotherapybusiness.industryLow doseHematologyGeneral MedicineProgression-Free SurvivalCancer treatmentClinical trialSurvival RateSystematic reviewOncologyClinical Trials Phase III as TopicClinical evidence030220 oncology & carcinogenesisAdministration MetronomicbusinessActa oncologica (Stockholm, Sweden)
researchProduct

Unusual giant chromophobe renal cancer totally managed with laparoscopic technique: Report of a case

2020

Highlights • We describe a case report of giant renal cell chromophobe carcinoma totally treated by laparoscopic surgery. • The size of renal lesion represents a critical point in surgical approach because to perform a laparoscopic radical nephrectomy can be challenging even for skilled surgeons in giant renal tumors. • A brief review of literature was performed to identify outcomes and potentially surgical advantages of laparoscopic approach for retroperitoenal liposarcoma. • The possibility of the laparoscopic approach derives from from the preoperative identification of adipose cleavage, from the absence of invasion of major vascular axes, from the absence of distant metastatic lesions.

medicine.medical_specialtymedicine.medical_treatmentChromophobe Renal Cell CarcinomaCase ReportChromophobe cellLesion03 medical and health sciences0302 clinical medicinemedicineAtypiaGiant renal massKidneybiologybusiness.industryCD117medicine.diseaseNephrectomyLaparoscopic nephrectomyChromophobe carcinomamedicine.anatomical_structureTumor progression030220 oncology & carcinogenesisbiology.proteinLaparoscopy030211 gastroenterology & hepatologySurgeryRadiologymedicine.symptombusinessInternational Journal of Surgery Case Reports
researchProduct

Chronic kidney disease and dyslipidaemia

2016

Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and …

medicine.medical_specialtymedicine.medical_treatmentRenal functionDisease030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumans030212 general & internal medicineRenal replacement therapyRenal Insufficiency ChronicIntensive care medicineDyslipidemiasGeneral Environmental ScienceCardiovascular mortalitybusiness.industryAnticholesteremic AgentsGeneral EngineeringCholesterol LDLmedicine.diseaseRenal Replacement TherapyCardiovascular DiseasesRenal transplantDisease ProgressionPhysical therapyGeneral Earth and Planetary SciencesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessVery high riskDyslipidemiaKidney diseaseClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Urethral recurrence of transitional cell carcinoma in a female patient after cystectomy and orthotopic ileal neobladder.

2000

A 63-year-old woman presented elsewhere with a unifocal pT1, G3 transitional cell carcinoma at the bladder base in 1995. She underwent urethral sparing cystectomy and ileal neobladder. Intraoperative frozen section from the proximal urethra did not demonstrate tumor involvement. Final histological examination revealed pT1, pN2, G3 transitional cell carcinoma. Adjuvant chemotherapy was not given. In 1998 the patient had symptoms of obstructive voiding due to a 3 3 3 cm. solid mass at the neobladder-urethra anastomosis (see figure). After 6 cycles of methotrexate, vinblastine, doxorubicin and cisplatin and a transient tumor size reduction, the patient was referred to us for local tumor progre…

medicine.medical_specialtymedicine.medical_treatmentUrologyUrologyAnastomosisUrinary Diversionurologic and male genital diseasesCystectomyCystectomyUreterFatal OutcomemedicineHumansCarcinoma Transitional CellUrethral NeoplasmsUrinary bladderbusiness.industryUrinary diversionMiddle Agedmedicine.diseaseSurgeryTransitional cell carcinomaUrethramedicine.anatomical_structureUrinary Bladder NeoplasmsTumor progressionFemaleNeoplasm Recurrence LocalbusinessThe Journal of urology
researchProduct

The progression rate of aortic stenosis: key to tailoring the management and potential target for treatment

2021

: Aortic stenosis is the most frequent valvular disease to require intervention in the western world and has always been featured as a progressive disease. The rate of progression can be assessed by carefully performed Doppler echocardiography and can vary greatly between individuals with a profound impact on prognosis. Unfortunately, the determinants of disease progression had been insufficiently studied and remain challenging to define, particularly in the outpatient setting. Multiple factors have been proposed and tested, but at present, there are no proven therapies to slow the course of the stenotic process. Heart valve clinics may be particularly important to define the progression ra…

medicine.medical_specialtyprogression rateaortic stenosis degenerative progression rate valvulopathies030204 cardiovascular system & hematologyDoppler echocardiography03 medical and health sciences0302 clinical medicineValvular diseaseRisk FactorsmedicineHumansdegenerative030212 general & internal medicineHeart valveIntensive care medicinemedicine.diagnostic_testbusiness.industryDisease progressionaortic stenosisGeneral MedicineAortic Valve Stenosismedicine.diseasePrognosisvalvulopathiesEchocardiography DopplerStenosismedicine.anatomical_structureaortic stenosis; degenerative; progression rate; valvulopathiesAortic valve stenosisDisease ProgressionProgression rateCardiology and Cardiovascular MedicinebusinessProgressive disease
researchProduct

Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer

2013

Background & Aims Pancreatic ductal adenocarcinoma (PDA) is an aggressive tumor, and patients typically present with late-stage disease; rates of 5-year survival after pancreaticoduodenectomy are low. Antibodies against α-enolase (ENO1), a glycolytic enzyme, are detected in more than 60% of patients with PDA, and ENO1-specific T cells inhibit the growth of human pancreatic xenograft tumors in mice. We investigated whether an ENO1 DNA vaccine elicits antitumor immune responses and prolongs survival of mice that spontaneously develop autochthonous, lethal pancreatic carcinomas. Methods We injected and electroporated a plasmid encoding ENO1 (or a control plasmid) into Kras G12D /Cre (KC) mice …

medicine.medical_treatmentDNA Vaccine; Enolase; Parnceratic cancer; Transgeneic miceEnolasegenetically engineered miceceEnzyme-Linked Immunosorbent AssayTransgeneic miceDNA vaccination03 medical and health sciencesMice0302 clinical medicineImmune systemPancreatic cancerGenetic modelmedicineVaccines DNADNA VaccineAnimalsSurvival rate030304 developmental biology0303 health sciencesImmunity CellularHepatologybiologyENO.1; DNA Vaccine; genetically engineered miceceVaccinationGastroenterologyParnceratic cancerImmunotherapyNeoplasms Experimentalmedicine.diseaseImmunohistochemistryMice Mutant Strains3. Good healthPancreatic NeoplasmsSurvival RateSettore BIO/18 - GeneticaTumor progression030220 oncology & carcinogenesisPhosphopyruvate HydrataseImmunologybiology.proteinAntibodyENO.1Carcinoma Pancreatic Ductal
researchProduct

Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.

2005

Type I interferons are associated with lupus. Genes that are regulated by IFN-alpha are upregulated in pediatric lupus patients. Gene deletion of the IFN-alpha/beta receptor in experimental lupus-like NZB mice results in reduced disease activity. Conversely, IFN-beta is a well-established treatment in multiple sclerosis, another autoimmune disease. For determining whether IFN-beta treatment is harmful or beneficial in lupus, MRL-Fas(lpr) mice were injected with this type I IFN. Treatment was initiated in MRL-Fas(lpr) mice with mild and advanced disease. IFN-beta was highly effective in prolonging survival and ameliorating the clinical (renal function, proteinuria, splenomegaly, and skin les…

medicine.medical_treatmentLupus nephritisImmunoglobulinsurologic and male genital diseasesmedicine.disease_causeKidneyAutoimmunityMiceImmune systemimmune system diseasesmedicineAnimalsLupus Erythematosus SystemicUreaskin and connective tissue diseasesSkinAutoimmune diseaseLupus erythematosusSystemic lupus erythematosusbusiness.industryGeneral MedicineImmunotherapymedicine.diseaseFlow CytometryLupus NephritisMice Mutant StrainsRecombinant ProteinsDisease Models AnimalProteinuriaCytokineNephrologyImmunoglobulin GImmunologyInterferon Type IDisease ProgressionbusinessCell DivisionJournal of the American Society of Nephrology : JASN
researchProduct